Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivekimab Sunirine + Venetoclax + Azacitidine in Newly Diagnosed AML Ineligible for Intensive Chemotherapy
2025-523724-47-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised trial of pivekimab sunirine in acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoints: Complete remission (CR) - Phase 2, Complete remission (CR) - Phase 3 and 2 more. Planned start Aug 2026; status: authorised.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-523724-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523724-47-00.